课题基金 / 基金详情

Translational Development of a novel therapy for Malignant Mesothelioma

Translational Development of a novel therapy for Malignant Mesothelioma
恶性间皮瘤新疗法的转化开发
批准号:
10026944
负责人:
金额:
$71.87万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
据估计,英国有250万癌症患者,预计到2030年将增加到400万。许多癌症的治疗和结果都有所改善,但对恶性间皮瘤(MM)等罕见的侵袭性癌症并不是如此。MM是一种无法治愈的肺部和胸部(胸膜)或腹膜(腹膜)衬里的癌症,通常由暴露于石棉纤维引起。尽管接受多种治疗(化疗、放射治疗和手术),MM仍被视为晚期疾病,中位生存期仅为14.8个月。只有不到5%的患者存活5年或更长时间,是所有癌症中存活率最低的癌症之一。只有两种化疗药物可能适用,患者通常会对它们产生耐药性。在过去的10年里,由伍尔弗汉普顿大学王伟光教授领导的多学科科学团队研究并证明了双硫兰(DS),一种60多年来在数百万患者中常规用于治疗酒精中毒的药物,对MM具有良好的活性。虽然DS在实验室中效果良好,但在临床试验中从未被证明是令人满意的。这主要是由于DS在血液中的半衰期极短(<4分钟)。王教授已经找到了一种将药物包裹在PLGA聚合物微粒中的方法,可以防止DS在体内降解并控制其释放。当在癌症小鼠身上进行测试时,这种胶囊药物已经取得了令人振奋的研究结果。这个项目的目的是对疗效和作用机制进行必要的评估,以便该团队能够在临床试验中取得进展。该项目的合作团队--双硫康、Pharmidex制药服务公司和伍尔弗汉普顿大学--以前在开发这种新疗法的初始阶段就曾成功地合作过。双硫康是2018年从伍尔弗汉普顿大学剥离出来的一家公司,拥有与胶囊DS相关的专利和其他知识产权,现在专注于将这种疗法推向临床。合作伙伴专注于间皮瘤,因为这种疾病是一种“孤儿疾病”,因为它很罕见,而且缺乏任何非常有效的治疗方法。英国监管机构MHRA在治疗指定孤儿疾病的费用和程序方面提供帮助,这意味着为患者批准药物的成本和时间尺度减少了。
英文摘要
There are an estimated 2.5 million people living with cancer in the UK, projected to increase up to 4 million by 2030\. Treatments and the outcomes for many cancers have improved, but not for rare, aggressive cancers such as Malignant Mesothelioma (MM). MM is an incurable cancer of the lining of the lung and chest (pleura) or abdominal cavity (peritoneum), typically caused by exposure to asbestos fibres. Despite multimodal treatment (chemotherapy, radiotherapy and surgery), MM is regarded as a terminal condition with a median survival of just 14.8 months. Fewer than 5% of patients survive for 5 years or more, representing one of the worst survival rates among all cancers. Only 2 chemotherapy drugs are potentially applicable and patients normally develop resistance to them.Over the last 10 years, a multidisciplinary scientific team led by Professor Weiguang Wang at the University of Wolverhampton have researched and demonstrated that Disulfiram (DS), a drug used routinely for the treatment of alcoholism in millions of patients over more than 60 years, has excellent activity against MM. Whilst DS works well in the laboratory, it has never proven satisfactory in clinical trials. This is mainly due to the extremely short half-life of DS in the bloodstream (< 4 min). Professor Wang has found a way of encapsulating the drug in PLGA polymeric micro particles that protects the DS from degradation in the body and controls its release. Promising research results have been achieved for the encapsulated drug when tested in mice with cancer. The aim of this project is to carry out the necessary evaluation of efficacy and mechanism of action so that the team can progress towards clinical trials.The collaborating team on the project -- Disulfican, Pharmidex Pharmaceutical Services and the University of Wolverhampton -- have successfully worked together before, in the initial stages of developing this new therapy. Disulfican was created as a spin-out company from the University of Wolverhampton in 2018, owns the patents and other intellectual property related to encapsulated DS, and is now focussed on advancing this therapy into clinic.The partners focussed on mesothelioma because this condition is an 'orphan disease', due to its rarity and the absence of any very effective treatments. The UK regulator MHRA gives assistance with fees and procedures for therapies to address designated orphan diseases which means that the costs and timescales to get the drug approved for patients is reduced.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
水稻边界发育缺陷突变体abnormal boundary development(abd)的基因克隆与功能分析
Development of a Linear Stochastic Model for Wind Field Reconstruction from Limited Measurement Data
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    40万元
  • 批准年份:
    2020
  • 负责人:
    Vikrant Gupta
  • 依托单位: